路透7月22日 - Repligen公司(RGEN.O)周三表示,将以约15亿美元的价格收购细胞和基因治疗工具制造商BioLife Solutions(BLFS.O),以扩大其在快速增长的细胞治疗市场中的业务版图。
路透7月22日 - Repligen公司(RGEN.O)周三表示,将以约15亿美元的价格收购细胞和基因治疗工具制造商BioLife Solutions(BLFS.O),以扩大其在快速增长的细胞治疗市场中的业务版图。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.